All News
SpA: Etiology to Diagnosis to Treatment - An Abstract Roundup
Here's a review of ten abstracts and presentations on spondyloarthritis encompassing a wide range of topics from etiology to diagnosis to treatment.
Read Article
The EMA's CHMP has recommended upadacitinib (Rinvoq) as an indication for the treatment of adults with active Psoriatic Arthritis and Ankylosing Spondylitis. https://t.co/0PKm90mo7F
Links:
Dr. John Cush RheumNow ( View Tweet)
Delays in Diagnosis - Axial Spondyloarthritis: Dr Antoni Chan ( @synovialjoints) reviews abstracts #1303 and #1306 presented at the #ACR20.
https://t.co/k7L2ebXcGb https://t.co/6oQ8fWpVCQ
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @KDAO2011 : #FDA updates 6/16/20 canakinumab for AOSD 5/29/20 ixekizumab for nr-AxSpa 80 mg q4wks 3/9/20 nintedanib for progressive ILD 1/29/20 and 6/16/20 secukinumab nr-axSpa 150 mg q4wks, AS 300 mg SQ q4weeks 1/17/20 belimumab label for black pts removed
Dr. John Cush RheumNow ( View Tweet)
Revisit #ACR20 through our podcast!
Best Practices for APL Testing,
Is COVID19 infection bad for rheumatic disease patients?
Pregnancy in SpA Patients
A New Pathway (Deucravacitinib) in Psoriatic Arthritis
https://t.co/kmoOL4d3oF https://t.co/qQQd1aJm8K
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @doctorRBC : AxSpa pts had Significant Gut Microbiome Differences in:
1⃣Disease activity and duration
2⃣Enthesitis
3⃣Radiographic involvement
Abs#1853 https://t.co/ynemrgsP3W
Dr. John Cush RheumNow ( View Tweet)
Tight Control Tune: Third Verse, Same as the First? TICOSPA. Dr. Jeff Curtis ( @RADoctor) reviews abstract #1444 at #ACR20.
https://t.co/4tqWuzwn54 https://t.co/u0vn4d1yF8
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @uptoTate : Study out of China, #ABS1892 shows that patient reported outcomes using self assessments are important in AS T2T and decreasing flare rates #ACR20 @RheumNow. https://t.co/vWjvAEeDMi https://t.co/HdMKSkkJ8I
Links:
Dr. John Cush RheumNow ( View Tweet)
Missing the Mark: AxSpa Treat to Target (TICOSPA Trial): Dr. Lianne Gensler #ACR20
https://t.co/ePrhQ90kwD
Links:
Dr. John Cush RheumNow ( View Tweet)
Pregnancy in SpA Patients: Dr Rachel Tate ( @uptoTate) #ACR20
https://t.co/GPrwd9HU5W https://t.co/TbwN4dZNul
Links:
Dr. John Cush RheumNow ( View Tweet)
New Treatments in Axial Spondyloarthritis: Dr. Antoni Chan ( @synovialjoints) discuses two abstracts presented at the #ACR20 annual meeting.
https://t.co/bh7l6C8p7P https://t.co/RN60iWCmet
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Conway ( @RichardPAConway) and Dr. Maguire discuss abstract #1323 presented at the #ACR20 on pregnancy in Spondyloarthritis.
https://t.co/YyWOuiq3jn https://t.co/SnodUbKZTx
Links:
Dr. John Cush RheumNow ( View Tweet)
SpA: Etiology to Diagnosis to Treatment - An Abstract Roundup by Dr. Robert Chao ( @doctorRBC) #ACR20
https://t.co/wR0inoR8jp https://t.co/7SFkThkPSr
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @doctorRBC : Gender disparity in Ankylosing Spondylitis symptoms.
1⃣Women ⬆️Achilles tendonitis, plantar fasciitis, joint swelling, BASDAI>40, DMARD use
2⃣HLA-B not associated w/ enthesitis
@RheumNow #ACR20 Abs#1872 https://t.co/pBcpuqgq0K https://t.co/YWKFUdIgMl
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @ejdein1 : #ACR20 Abs#L11. Efficacy of TOFA vs PBO in AS. At week 16, %ASAS20 responders 56% v 29% PBO; %ASAS40 40% vs 12%. @RheumNow #ACRBest https://t.co/knduk3l6xV https://t.co/SNommxn1jA
Links:
Dr. John Cush RheumNow ( View Tweet)
Nomenclature, Uveitis and Other Spondyloarthritis Features with Dr. Lianne Gensler #ACR20
https://t.co/zql7iySXOA https://t.co/PY9k108QTc
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @synovialjoints : Can we find Axial Spa (FaxSpa) using social media? This study used an online screening tool (A-tool) on social media in patients with back pain. 42% had a positive screen and referred for review @RheumNow #ACR20 Abstr#1894
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @synovialjoints : The majority of patients with axSpA were able to use an axSpA smartphone app. recording BASDAI, BASFI 2 weekly. Current disease activity influence adherence to reporting @RheumNow #ACR20 Abstr#1890
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @DrPetryna : #ACR20 abs1535 retrospective study of SI MRI reveals 20% pts w/out spondyloarthritis have BME on an MRI, predominantly in the antero-middle quadrant. Erosions were seen in 31% of healthy patients and in 61% of patients with spondyloarthritis
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @Janetbirdope : Filgo decreased MRI inflammation of many structures early in Rx in SpA which seems novel says w Maksymowych 5M015 @RheumNow #ACR20 @CRASCRRheum #ACRbest https://t.co/5HQiIettjh https://t.co/NwFMkLIhWw
Links:
Dr. John Cush RheumNow ( View Tweet)
